Systems medicine in oncology: Signaling network modeling and new-generation decision-support systems

Silvio Parodi, Giuseppe Riccardi, Nicoletta Castagnino, Lorenzo Tortolina, Massimo Maffei, Gabriele Zoppoli, Alessio Nencioni, Alberto Ballestrero, Franco Patrone

Research output: Chapter in Book/Report/Conference proceedingChapter

6 Citations (Scopus)

Abstract

Two different perspectives are the main focus of this book chapter: (1) A perspective that looks to the future, with the goal of devising rational associations of targeted inhibitors against distinct altered signaling-network pathways. This goal implies a sufficiently in-depth molecular diagnosis of the personal cancer of a given patient. A sufficiently robust and extended dynamic modeling will suggest rational combinations of the abovementioned oncoprotein inhibitors. The work toward new selective drugs, in the field of medicinal chemistry, is very intensive. Rational associations of selective drug inhibitors will become progressively a more realistic goal within the next 3-5 years. Toward the possibility of an implementation in standard oncologic structures of technologically sufficiently advanced countries, new (legal) rules probably will have to be established through a consensus process, at the level of both diagnostic and therapeutic behaviors. (2) The cancer patient of today is not the patient of 5-10 years from now. How to support the choice of the most convenient (and already clinically allowed) treatment for an individual cancer patient, as of today? We will consider the present level of artificial intelligence (AI) sophistication and the continuous feeding, updating, and integration of cancer-related new data, in AI systems. We will also report briefly about one of the most important projects in this field: IBM Watson US Cancer Centers. Allowing for a temporal shift, in the long term the two perspectives should move in the same direction, with a necessary time lag between them.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages181-219
Number of pages39
Volume1386
DOIs
Publication statusPublished - Jan 1 2016

Publication series

NameMethods in Molecular Biology
Volume1386
ISSN (Print)10643745

Fingerprint

Systems Analysis
Artificial Intelligence
Neoplasms
Pharmaceutical Chemistry
Oncogene Proteins
Pharmaceutical Preparations
Therapeutics

Keywords

  • Artificial intelligence
  • Cancer genomics
  • Decision-support systems
  • IBM Watson
  • Individual cancer patient
  • New clinical trial designs
  • Oncoprotein inhibitors
  • Rational associations of targeted inhibitors
  • Signaling-network pathways
  • Systems medicine

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Parodi, S., Riccardi, G., Castagnino, N., Tortolina, L., Maffei, M., Zoppoli, G., ... Patrone, F. (2016). Systems medicine in oncology: Signaling network modeling and new-generation decision-support systems. In Methods in Molecular Biology (Vol. 1386, pp. 181-219). (Methods in Molecular Biology; Vol. 1386). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-3283-2_10

Systems medicine in oncology : Signaling network modeling and new-generation decision-support systems. / Parodi, Silvio; Riccardi, Giuseppe; Castagnino, Nicoletta; Tortolina, Lorenzo; Maffei, Massimo; Zoppoli, Gabriele; Nencioni, Alessio; Ballestrero, Alberto; Patrone, Franco.

Methods in Molecular Biology. Vol. 1386 Humana Press Inc., 2016. p. 181-219 (Methods in Molecular Biology; Vol. 1386).

Research output: Chapter in Book/Report/Conference proceedingChapter

Parodi, S, Riccardi, G, Castagnino, N, Tortolina, L, Maffei, M, Zoppoli, G, Nencioni, A, Ballestrero, A & Patrone, F 2016, Systems medicine in oncology: Signaling network modeling and new-generation decision-support systems. in Methods in Molecular Biology. vol. 1386, Methods in Molecular Biology, vol. 1386, Humana Press Inc., pp. 181-219. https://doi.org/10.1007/978-1-4939-3283-2_10
Parodi S, Riccardi G, Castagnino N, Tortolina L, Maffei M, Zoppoli G et al. Systems medicine in oncology: Signaling network modeling and new-generation decision-support systems. In Methods in Molecular Biology. Vol. 1386. Humana Press Inc. 2016. p. 181-219. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-3283-2_10
Parodi, Silvio ; Riccardi, Giuseppe ; Castagnino, Nicoletta ; Tortolina, Lorenzo ; Maffei, Massimo ; Zoppoli, Gabriele ; Nencioni, Alessio ; Ballestrero, Alberto ; Patrone, Franco. / Systems medicine in oncology : Signaling network modeling and new-generation decision-support systems. Methods in Molecular Biology. Vol. 1386 Humana Press Inc., 2016. pp. 181-219 (Methods in Molecular Biology).
@inbook{776673fb85ab45c689af3ae8807e7419,
title = "Systems medicine in oncology: Signaling network modeling and new-generation decision-support systems",
abstract = "Two different perspectives are the main focus of this book chapter: (1) A perspective that looks to the future, with the goal of devising rational associations of targeted inhibitors against distinct altered signaling-network pathways. This goal implies a sufficiently in-depth molecular diagnosis of the personal cancer of a given patient. A sufficiently robust and extended dynamic modeling will suggest rational combinations of the abovementioned oncoprotein inhibitors. The work toward new selective drugs, in the field of medicinal chemistry, is very intensive. Rational associations of selective drug inhibitors will become progressively a more realistic goal within the next 3-5 years. Toward the possibility of an implementation in standard oncologic structures of technologically sufficiently advanced countries, new (legal) rules probably will have to be established through a consensus process, at the level of both diagnostic and therapeutic behaviors. (2) The cancer patient of today is not the patient of 5-10 years from now. How to support the choice of the most convenient (and already clinically allowed) treatment for an individual cancer patient, as of today? We will consider the present level of artificial intelligence (AI) sophistication and the continuous feeding, updating, and integration of cancer-related new data, in AI systems. We will also report briefly about one of the most important projects in this field: IBM Watson US Cancer Centers. Allowing for a temporal shift, in the long term the two perspectives should move in the same direction, with a necessary time lag between them.",
keywords = "Artificial intelligence, Cancer genomics, Decision-support systems, IBM Watson, Individual cancer patient, New clinical trial designs, Oncoprotein inhibitors, Rational associations of targeted inhibitors, Signaling-network pathways, Systems medicine",
author = "Silvio Parodi and Giuseppe Riccardi and Nicoletta Castagnino and Lorenzo Tortolina and Massimo Maffei and Gabriele Zoppoli and Alessio Nencioni and Alberto Ballestrero and Franco Patrone",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-3283-2_10",
language = "English",
volume = "1386",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "181--219",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Systems medicine in oncology

T2 - Signaling network modeling and new-generation decision-support systems

AU - Parodi, Silvio

AU - Riccardi, Giuseppe

AU - Castagnino, Nicoletta

AU - Tortolina, Lorenzo

AU - Maffei, Massimo

AU - Zoppoli, Gabriele

AU - Nencioni, Alessio

AU - Ballestrero, Alberto

AU - Patrone, Franco

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Two different perspectives are the main focus of this book chapter: (1) A perspective that looks to the future, with the goal of devising rational associations of targeted inhibitors against distinct altered signaling-network pathways. This goal implies a sufficiently in-depth molecular diagnosis of the personal cancer of a given patient. A sufficiently robust and extended dynamic modeling will suggest rational combinations of the abovementioned oncoprotein inhibitors. The work toward new selective drugs, in the field of medicinal chemistry, is very intensive. Rational associations of selective drug inhibitors will become progressively a more realistic goal within the next 3-5 years. Toward the possibility of an implementation in standard oncologic structures of technologically sufficiently advanced countries, new (legal) rules probably will have to be established through a consensus process, at the level of both diagnostic and therapeutic behaviors. (2) The cancer patient of today is not the patient of 5-10 years from now. How to support the choice of the most convenient (and already clinically allowed) treatment for an individual cancer patient, as of today? We will consider the present level of artificial intelligence (AI) sophistication and the continuous feeding, updating, and integration of cancer-related new data, in AI systems. We will also report briefly about one of the most important projects in this field: IBM Watson US Cancer Centers. Allowing for a temporal shift, in the long term the two perspectives should move in the same direction, with a necessary time lag between them.

AB - Two different perspectives are the main focus of this book chapter: (1) A perspective that looks to the future, with the goal of devising rational associations of targeted inhibitors against distinct altered signaling-network pathways. This goal implies a sufficiently in-depth molecular diagnosis of the personal cancer of a given patient. A sufficiently robust and extended dynamic modeling will suggest rational combinations of the abovementioned oncoprotein inhibitors. The work toward new selective drugs, in the field of medicinal chemistry, is very intensive. Rational associations of selective drug inhibitors will become progressively a more realistic goal within the next 3-5 years. Toward the possibility of an implementation in standard oncologic structures of technologically sufficiently advanced countries, new (legal) rules probably will have to be established through a consensus process, at the level of both diagnostic and therapeutic behaviors. (2) The cancer patient of today is not the patient of 5-10 years from now. How to support the choice of the most convenient (and already clinically allowed) treatment for an individual cancer patient, as of today? We will consider the present level of artificial intelligence (AI) sophistication and the continuous feeding, updating, and integration of cancer-related new data, in AI systems. We will also report briefly about one of the most important projects in this field: IBM Watson US Cancer Centers. Allowing for a temporal shift, in the long term the two perspectives should move in the same direction, with a necessary time lag between them.

KW - Artificial intelligence

KW - Cancer genomics

KW - Decision-support systems

KW - IBM Watson

KW - Individual cancer patient

KW - New clinical trial designs

KW - Oncoprotein inhibitors

KW - Rational associations of targeted inhibitors

KW - Signaling-network pathways

KW - Systems medicine

UR - http://www.scopus.com/inward/record.url?scp=84950300744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950300744&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-3283-2_10

DO - 10.1007/978-1-4939-3283-2_10

M3 - Chapter

AN - SCOPUS:84950300744

VL - 1386

T3 - Methods in Molecular Biology

SP - 181

EP - 219

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -